{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:40:41Z","timestamp":1793338841330,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100005089","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7242143"],"award-info":[{"award-number":["7242143"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capital's Funds for Health Improvement and Research","award":["2024-2-4076"],"award-info":[{"award-number":["2024-2-4076"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2024IR42"],"award-info":[{"award-number":["2024IR42"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2019-I2M-5-046"],"award-info":[{"award-number":["2019-I2M-5-046"]}]},{"name":"Peking University First Hospital Cross-Research Project","award":["2023IR35"],"award-info":[{"award-number":["2023IR35"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3503504"],"award-info":[{"award-number":["2023YFC3503504"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Science Research Project of Hebei","award":["20240407"],"award-info":[{"award-number":["20240407"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study aimed to evaluate the efficacy and safety of telitacicept for the treatment of lupus nephritis (LN) in real-world clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adult patients with LN receiving additional telitacicept at 80\/160\u00a0mg once per week were recruited, while patients receiving only standard therapy were included as the control group using a 1:1 propensity score\u2013matching approach. The primary outcomes were the proportions of patients achieving complete renal response (CRR) and primary efficacy renal response (PERR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-four patients in both the control and telitacicept groups were enrolled, with median follow-up periods of 10.78\u00a0\u00b1\u00a03.37 and 10.5\u00a0\u00b1\u00a03.78\u00a0months, respectively. Compared with the control group, a significant improvement was observed in the proportion of patients achieving CRR (11.36% vs 29.55%, P\u00a0=\u00a0.034) and PERR (45.45% vs 68.18%, P\u00a0=\u00a0.031) in the telitacicept group at the last visit. Median proteinuria was reduced by 0.97\u00a0g\/day (63.82%) from baseline in the telitacicept group, compared with a reduction of 0.31\u00a0g\/day (25.31%) in the control group. Additionally, the telitacicept group showed notable treatment responses in the median SLE Disease Activity Index-2000 score, Physician's Global Assessment score and glucocorticoid dose reduction. Subgroup analysis revealed that telitacicept exhibited a more prominent therapeutic effect in patients with type V LN and those with proteinuria exceeding 3\u00a0g\/day. Telitacicept was well tolerated, and the incidence of adverse events was similar between the two groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>LN patients receiving additional telitacicept treatment demonstrated better disease remission, particularly in those with type V LN and proteinuria \u22653\u00a0g\/day, with a favorable safety profile in real-world clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf049","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T05:23:17Z","timestamp":1741324997000},"page":"1775-1785","source":"Crossref","is-referenced-by-count":11,"title":["Real world data on dual BLyS\/APRIL inhibition with telitacicept for lupus nephritis"],"prefix":"10.1093","volume":"40","author":[{"given":"Jingjing","family":"Jin","sequence":"first","affiliation":[{"name":"Chinese Academy of Medical Sciences Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China; Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, , Beijing ,","place":["PR China"]},{"name":"Hebei Clinical Research Center for Chronic Kidney Disease Departments of Nephrology, The Fourth Hospital of Hebei Medical University, Hebei Key Laboratory of Vascular Calcification in Kidney Disease, , Shijiazhuang, Hebei ,","place":["PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Tan","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China; Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, , Beijing ,","place":["PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tan","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China; Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, , Beijing ,","place":["PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China; Research Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, , Beijing ,","place":["PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"2025082900415510700_bib1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"2025082900415510700_bib2","doi-asserted-by":"publisher","first-page":"648727","DOI":"10.3389\/fmed.2021.648727","article-title":"Frequency of systemic lupus erythematosus was decreasing among hospitalized patients from 2013 to 2017 in a national database in China","volume":"8","author":"Tan","year":"2021","journal-title":"Front Med"},{"key":"2025082900415510700_bib3","doi-asserted-by":"publisher","first-page":"102871","DOI":"10.1016\/j.jaut.2022.102871","article-title":"Lupus nephritis: new progress in diagnosis and treatment","volume":"132","author":"Yu","year":"2022","journal-title":"J Autoimmun"},{"key":"2025082900415510700_bib4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40272-023-00609-3","article-title":"Managing lupus nephritis in children and adolescents","volume":"26","author":"Chan","year":"2024","journal-title":"Pediatr Drugs"},{"key":"2025082900415510700_bib5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/rheumatology\/kead629","article-title":"Real-world efficacy of belimumab in systemic lupus erythematosus: a prospective cohort from a single center in China","volume":"64","author":"Zhao","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2025082900415510700_bib6","doi-asserted-by":"publisher","first-page":"102691","DOI":"10.1016\/j.autrev.2020.102691","article-title":"Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: a systemic review and meta-analysis","volume":"20","author":"Shi","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2025082900415510700_bib7","doi-asserted-by":"publisher","first-page":"1169084","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Immunol"},{"key":"2025082900415510700_bib8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int Rev Immunol"},{"key":"2025082900415510700_bib9","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"2025082900415510700_bib10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025082900415510700_bib11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s10157-024-02501-x","article-title":"Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study","volume":"28","author":"Huang","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"2025082900415510700_bib12","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.ijsu.2014.07.014","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"12","author":"Vandenbroucke","year":"2014","journal-title":"Int J Surg"},{"key":"2025082900415510700_bib13","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025082900415510700_bib14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of lupus nephritis","volume":"105","author":"Kidney disease: improving global outcomes Lupus nephritis work G","year":"2024","journal-title":"Kidney Int"},{"key":"2025082900415510700_bib15","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"2025082900415510700_bib16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000529675","article-title":"Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China","volume":"9","author":"Tan","year":"2023","journal-title":"Kidney Dis"},{"key":"2025082900415510700_bib17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.kint.2024.10.018","article-title":"Lupus nephritis: redefining the treatment goals","volume":"107","author":"De Vriese","year":"2025","journal-title":"Kidney Int"},{"key":"2025082900415510700_bib18","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2025082900415510700_bib19","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025082900415510700_bib20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025082900415510700_bib21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3892\/etm.2024.12660","article-title":"Efficacy and safety of telitacicept in patients with lupus nephritis","volume":"28","author":"Zhu","year":"2024","journal-title":"Exp Ther Med"},{"key":"2025082900415510700_bib22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025082900415510700_bib23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"2025082900415510700_bib24","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/1529-0131(200008)43:8&lt;1801::AID-ANR16&gt;3.0.CO;2-O","article-title":"Damage in systemic lupus erythematosus and its association with corticosteroids","volume":"43","author":"Zonana-Nacach","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2025082900415510700_bib25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025082900415510700_bib26","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3760\/cma.j.cn112138-20210609-00410","article-title":"Recommendations for the diagnosis and management of lupus nephritis in China]","volume":"60","author":"Zhang","year":"2021","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2025082900415510700_bib27","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1002\/mco2.515","article-title":"B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept","volume":"5","author":"Ji","year":"2024","journal-title":"MedComm"},{"key":"2025082900415510700_bib28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","article-title":"The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study","volume":"32","author":"Chen","year":"2023","journal-title":"Lupus"},{"key":"2025082900415510700_bib29","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/CJN.02520322","article-title":"Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study","volume":"17","author":"Furie","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025082900415510700_bib30","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/rheumatology\/kead707","article-title":"Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study","volume":"64","author":"Sishi","year":"2025;","journal-title":"Rheumatology (Oxford)"},{"key":"2025082900415510700_bib31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40259-024-00676-z","article-title":"A population pharmacokinetic model of tocilizumab in kidney transplant patients treated for chronic active antibody-mediated rejection: comparison of plasma exposure between intravenous and subcutaneous administration schemes","volume":"38","author":"Arriv\u00e9","year":"2024","journal-title":"BioDrugs"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf049\/62310215\/gfaf049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/9\/1775\/62310215\/gfaf049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/9\/1775\/62310215\/gfaf049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T04:42:05Z","timestamp":1756442525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/9\/1775\/8058889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,3,6]]},"published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf049","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,3,6]]}}}